JYP0061

DRUG2 trials

Sponsors

Guangzhou JOYO Pharma Co., Ltd

Conditions

Healthy SubjectsNeuromyelitis Optica Spectrum Disorders

Phase 1

Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.

CompletedNCT06137911

Guangzhou JOYO Pharma Co., LtdHealthy Subjects

Start: 2021-09-26End: 2022-11-09Updated: 2023-12-01

Phase 2

A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)

RecruitingNCT06697535

Guangzhou JOYO Pharma Co., LtdNeuromyelitis Optica Spectrum Disorders

Start: 2023-05-24End: 2026-07-30Target: 35Updated: 2024-11-20